Streetbeat News

Legal Regulatory

IMX

Immutable (IMX) successfully concluded an SEC investigation without any enforcement action, marking a significant milestone for Web3 gaming. The SEC dropped its probe into the company's 2021 token listing and private sales, with no findings of wrongdoing. This development aligns with a broader trend of reduced regulatory pressure on crypto firms under the current administration.

Portfolio Pulse from

March 26, 2025 | 7:15 am

NYXH

Nyxoah SA has received an Approvable Letter from the FDA for its Genio® system, a neurostimulation therapy for Obstructive Sleep Apnea (OSA). The letter indicates that the Pre-Market Approval (PMA) application substantially meets regulatory requirements, pending a final review of manufacturing facilities and methods. The company remains committed to bringing this innovative therapy to U.S. patients.

Portfolio Pulse from

March 26, 2025 | 7:15 am

CRWV

MSFT

NVDA

CoreWeave, an AI cloud computing company, is preparing for an IPO with significant financial risks. The company has $8B in loans with high interest rates and relies heavily on major tech customers like Microsoft and Nvidia. Declining GPU prices and potential customer concentration pose substantial challenges to its long-term financial sustainability.

Portfolio Pulse from

March 26, 2025 | 7:15 am

SMTC

Law firm Levi & Korsinsky has filed a class action securities lawsuit against Semtech Corporation, alleging securities fraud between August 27, 2024 and February 7, 2025. The lawsuit claims Semtech made false statements about its CopperEdge products, including product performance, customer needs, and sales expectations for fiscal 2026.

Portfolio Pulse from

March 26, 2025 | 7:15 am

ZUUZF

President Donald J. Trump signed an Executive Order on March 20, 2025, aimed at accelerating domestic critical mineral production, with a specific focus on copper. The order invokes the Defense Production Act to expedite permit approvals and create a dedicated mineral production fund. Zeus North America Mining Corp., with its Cuddy Mountain copper project in Idaho, stands to potentially benefit from this initiative.

Portfolio Pulse from

March 26, 2025 | 7:15 am

ZUUZF

President Donald J. Trump signed an Executive Order on March 20, 2025, aimed at accelerating domestic critical mineral production, with a specific focus on copper. The order invokes the Defense Production Act to expedite permit approvals and create a dedicated mineral production fund, potentially supporting companies like Zeus North America Mining Corp. in their exploration efforts.

Portfolio Pulse from

March 26, 2025 | 7:15 am

SMTC

Law firm Levi & Korsinsky has filed a class action securities lawsuit against Semtech Corporation, alleging securities fraud between August 27, 2024 and February 7, 2025. The lawsuit claims Semtech made false statements about its CopperEdge products, including product performance, customer needs, and sales expectations for fiscal 2026.

Portfolio Pulse from

March 26, 2025 | 7:15 am

NYXH

Nyxoah SA has received an Approvable Letter from the FDA for its Genio® system, a neurostimulation therapy for Obstructive Sleep Apnea (OSA). The letter indicates that the Pre-Market Approval (PMA) application substantially meets regulatory requirements, pending a final review of manufacturing facilities and methods. The company remains committed to bringing this innovative therapy to U.S. patients.

Portfolio Pulse from

March 26, 2025 | 7:15 am

NMRA

Levi & Korsinsky law firm is pursuing a class action lawsuit against Neumora Therapeutics (NMRA) alleging the company made false statements about its Phase Two clinical trials for Navacaprant, a therapeutic candidate for Major Depressive Disorder (MDD). The lawsuit claims Neumora manipulated trial inclusion criteria and statistical analysis to show favorable results, potentially misrepresenting the drug's efficacy.

Portfolio Pulse from

March 26, 2025 | 6:45 am

TNXP

Tonix Pharmaceuticals (TNXP) has successfully had its New Drug Application (NDA) for TNX-102 SL accepted by the FDA for treating fibromyalgia. This could potentially represent the first new fibromyalgia drug in 15 years, marking a significant milestone for the company's pharmaceutical development efforts.

Portfolio Pulse from

March 26, 2025 | 6:45 am